Bailard Inc. Sells 346 Shares of Sanofi (NASDAQ:SNY)

Bailard Inc. decreased its position in Sanofi (NASDAQ:SNY) by 2.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,267 shares of the company’s stock after selling 346 shares during the quarter. Bailard Inc.’s holdings in Sanofi were worth $759,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Cardinal Capital Management lifted its position in Sanofi by 0.3% during the 4th quarter. Cardinal Capital Management now owns 58,854 shares of the company’s stock worth $2,927,000 after buying an additional 201 shares in the last quarter. Daiwa Securities Group Inc. boosted its position in Sanofi by 3.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after acquiring an additional 216 shares during the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of Sanofi by 2.8% in the 3rd quarter. Sage Rhino Capital LLC now owns 8,722 shares of the company’s stock valued at $468,000 after buying an additional 240 shares during the last quarter. Gallacher Capital Management LLC boosted its holdings in shares of Sanofi by 4.5% in the 3rd quarter. Gallacher Capital Management LLC now owns 5,715 shares of the company’s stock valued at $307,000 after buying an additional 245 shares during the last quarter. Finally, Rise Advisors LLC lifted its holdings in Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Morgan Stanley assumed coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective on the stock. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Trading Down 0.5 %

Shares of SNY stock opened at $49.13 on Friday. The company has a market cap of $124.28 billion, a P/E ratio of 24.69, a PEG ratio of 1.49 and a beta of 0.61. The stock has a 50 day simple moving average of $47.71 and a two-hundred day simple moving average of $48.41. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $56.26.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a net margin of 10.52% and a return on equity of 19.69%. Research analysts forecast that Sanofi will post 4.09 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a dividend of $1.478 per share. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is 69.35%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.